ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

三项最新研究表明，胰高血糖素样肽-1（Glucagon-like peptide-1, GLP-1）药物，如 Ozempic（奥земпик），可能显著降低中风死亡率，改善脑损伤后的恢复，并可能降低整体中风风险。 在神经介入手术学会（Society ...

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who ...

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were ...

Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...